High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response
Mi Y., Burnham KL., Charles PD., Heilig R., Vendrell I., Whalley J., Torrance HD., Antcliffe DB., May SM., Neville MJ., Berridge G., Hutton P., Geoghegan CG., Radhakrishnan J., Nesvizhskii AI., Yu F., Davenport EE., McKechnie S., Davies R., O’Callaghan DJP., Patel P., del Arroyo AG., Karpe F., Gordon AC., Ackland GL., Hinds CJ., Fischer R., Knight JC., Webster N., Galley H., Taylor J., Hall S., Addison J., Roughton S., Tennant H., Guleri A., Waddington N., Arawwawala D., Durcan J., Short A., Swan K., Williams S., Smolen S., Mitchell-Inwang C., Errington E., Templeton M., Venatesh P., Ward G., McCauley M., Baudouin S., Higham C., Soar J., Grier S., Hall E., Brett S., Kitson D., Wilson R., Mountford L., Moreno J., Hall P., Hewlett J., Garrard C., Millo J., Young D., Parsons P., Smiths A., Faras-Arraya R., Soar J., Raymode P., Thompson J., Bowrey S., Kazembe S., Rich N., Andreou P., Hales D., Roberts E., Fletcher S., Rosbergen M., Glister G., Cuesta JM., Bion J., Millar J., Perry EJ., Willis H., Mitchell N., Ruel S., Carrera R., Wilde J., Nilson A., Lees S., Kapila A., Jacques N., Atkinson J., Brown A., Prowse H., Krige A., Bland M., Bullock L., Harrison D., Mills G., Humphreys J., Armitage K., Laha S., Baldwin J., Walsh A., Doherty N., Drage S., de Gordoa LO-R., Lowes S., Higham C., Walsh H., Calder V., Swan C., Payne H., Higgins D., Andrews S., Mappleback S., Garrard C., Watson D., McLees E., Purdy A., Stotz M., Ochelli-Okpue A., Bonner S., Whitehead I., Hugil K., Goodridge V., Cawthor L., Kuper M., Pahary S., Bellingan G., Marshall R., Montgomery H., Ryu JH., Bercades G., Boluda S., Bentley A., Mccalman K., Jefferies F., Kwok A., Maugeri N., Radhakrishnan J., Allcock A.
Sepsis, the dysregulated host response to infection causing life-threatening organ dysfunction, is a global health challenge requiring better understanding of pathophysiology and new therapeutic approaches. Here, we applied high-throughput tandem mass spectrometry to delineate the plasma proteome for sepsis and comparator groups (noninfected critical illness, postoperative inflammation, and healthy volunteers) involving 2612 samples (from 1611 patients) and 4553 liquid chromatography–mass spectrometry analyses acquired through a single batch of continuous measurements, with a throughput of 100 samples per day. We show how this scale of data can delineate proteins, pathways, and coexpression modules in sepsis and be integrated with paired leukocyte transcriptomic data (837 samples from n = 649 patients). We mapped the plasma proteomic landscape of the host response in sepsis, including changes over time, and identified features relating to etiology, clinical phenotypes (including organ failures), and severity. This work reveals subphenotypes informative for sepsis response state, disease processes, and outcome; identifies potential biomarkers; and advances opportunities for a precision medicine approach to sepsis.